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Nowadays, matrix-assisted laser desorption/ionization 
time-of-flight mass spectrometry (MALDI-TOF MS) has rev-
olutionized clinical microbiology laboratories and they have 
adopted it as a primary method for the identification of mi-
croorganisms [3]. It can be highlighted a study that shows 
that this technique represents a reliable identification tool 
for anaerobic bacteria. In spite of the special culture re-
quirements, their low growth-rate and the difficulties to 
isolate this kind of bacteria, MALDI-TOF MS only requires 
little amount of bacteria and allows high-throughput (Rod-
riguez-Sánchez B, et al; P2236). Can also be mentioned the 
possibility to make direct identification for most of the uro-
pathogens by this method. It can process a large number of 
urine samples (30 min per sample) with an accuracy of over 
90% (Ilki A, et al; P2237). Furthermore, the identification of 
non-tuberculous Mycobacteria isolates from MGITs® (Myco-
bacteria Growth Indicator Tubes, Becton Dickinson) can be 
rapid and reliably performed using MALDI-TOF MS by includ-
ing a sonication step in the sample processing method (Rod-
riguez-Sánchez B, et al; P2405).
Following the success of mass spectrometry (MS) for rou-
tine identification, several options were considered to extend 
the clinical applications of MALDI-TOF MS platforms. In one 
study, an innovative full MALDI-based approach to quickly 
detect carbapenemase-producing enterobacteria (CPE) in pos-
itive blood cultures was evaluated, applying the novel tools of 
Biotyper system (Bruker Daltonik) directly on the bacterial pel-
let extracted from the positive bottles (Cordovana M; O0811). 
KPC-producers were identified by the automated detection of 
the 11109 KPC-specific peak by the Biotyper software, while 
an imipenem hydrolysis assay was used to verify the carbap-
enemase activity. The full MALDI-based approach enabled the 
rapid detection of different kind of carbapenemases directly 
from the positive blood culture bottles, with absolute sensi-
tivity and specificity, and allowing a significant shortening of 
potential reporting time in comparison with the actual routine 
(30 min-2 h).
INTRODUCTION
The last European Congress of Clinical Microbiology and 
Infectious Diseases (ECCMID) held in Madrid (Spain), last April 
2018, was an undoubtful success for scientific quality and con-
ference affluency [1]. The congress covered the entire field of 
infectious diseases and clinical microbiology with a significant 
and important participation of scientist all over the world (more 
than 12,400 congresists from more than 120 countries). In fact, 
nowadays ECCMID has become the world congress of reference, 
for excellence and participation, the main meeting in clinical 
microbiology and infectious diseases. Designed with more than 
250 sessions, the key topics were antimicrobial resistance, novel 
diagnostic techniques, the role of microbiota, and new antimi-
crobials. In addition, the congress also covered different aspects 
of the big four in infectious diseases: bacterial, viral (HIV and 
hepatitis), fungal and parasitic infections. The complete program 
included a total number of 3,563 abstracts, more than a hundred 
of symposiums and oral sessions, 20 educational workshops and 
25 experts meetings. This minireview will try to summarize, from 
an objective point of view, the most important contributions, 
only focusing in three different aspects: microbiology diagnosis, 
resistance to antimicrobials, and new antimicrobials.
DIAGNOSTIC MICROBIOLOGICAL TECHNIQUES
Infectious diseases are an important cause of morbidity 
and mortality but in the past few decades, the diagnostic mi-
crobiological techniques have significatly evolved. Thanks to 
the progress of molecular methods, these not only identify but 
also detect antibiotic marker genes, fastidious bacteria, and 
uncultivable microbes [2].
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to the presence of other carbapenemases. For this reason, it 
should be performed in parallel to culture.
Bloodstream infections (BSI) by CPE are associated with 
treatment failure and increased mortality, so that it´s so im-
portant their rapid detection. Rapid immunochromatographic 
lateral flow tests (ICT) which detect epitopes specific for a car-
bapenemase have been recently developed for CPE detection 
from cultures on solid media. In one study, a protocol was de-
veloped and evaluated for the rapid detection of CPE directly 
from positive BC using a new ICT, which detects OXA-48-like, 
KPC and NDM carbapenemases (Hamprecht A, et al; O0810). 
This study demonstrates that with the new protocol OXA-48-
like, KPC and NDM carbapenemases can be reliably detected 
directly from positive BC bottles within 20-30 min (100% 
sensitivity, 100% specificity). This can help to rapidly identify 
patients with CPE BSI and optimize the treatment of patients. 
In addition, the global spread of carbapenem-resistant Acine-
tobacter baumannii (CRAb) has led to an emerging worldwide 
healthcare problem. There are six identified OXA-subgroups 
associated with carbapenem-resistance, where OXA-23 is the 
most prevalent carbapenem-resistance determinant among 
isolates followed by OXA-72 (OXA-40-like) and OXA-58 world-
wide. It has been developed an immunochromatographic 
lateral flow assay (OXA-23 K-SeT) able to detect OXA-23-like 
producing strains with 100 % specificity on bacterial colonies 
(Mertins S, et al; P2330). In this study, new monoclonal anti-
bodies (moabs) to detect OXA-40 and OXA-58 were presented. 
The resulting triple OXA-23/40/58 detection assay would be 
able to detect the most prevalent OXA-mediated CRAb. With 
this rapid detection assay, one can save 12-48 hours in diag-
nostics, avoiding treatment with inappropriate antibiotics and 
allowing an earlier intervention to control transmission of CR-
Ab.
The introduction of massive sequencing (next-generation 
sequencing, NGS) in genomics facilities has meant an exponen-
tial growth in data generation. With its ultra-high throughput, 
scalability, and speed, NGS enables researchers to perform a 
wide variety of applications. It enables scientists to analyze the 
entire human genome in a single sequencing experiment, or to 
sequence thousands to tens of thousands of genomes in one 
year. Next-generation sequencing-based pathogen detection 
is already being used by diagnostic laboratories from clinical 
specimens [6]. 
A study that compares Sanger sequencing (a commer-
cialized method of DNA sequencing) with NGS for detection 
of HIV drug resistance mutations in routine was presented 
(García-Arata MI, et al; P1902). All mutations previously de-
tected by Sanger were accurately detected by NGS. In addition, 
minority resistance-conferring mutations were also detect-
ed by NGS (even in low viral load-samples). This method can 
be affordable in three labor days and price is comparable or 
even lower that the conventional sequencing and the platform 
could be at the same time run for other uses, like genotyping 
hepatitis C or HIV tropism. All these findings made NGS an ef-
fective new strategy and useful tool to use for HIV resistance 
detection in routine labs.
There was another study where the development of a 
PCR-MALDI approach could unlock the potential of a system 
capable of detecting tens of targets simultaneously, without 
the need to culture (Green J, et al; P2376). This new technolo-
gy could provide many clinical advantages and support a syn-
dromic approach to the patient diagnosis. The results showed 
that combining the large instrument installed base with re-
al-time PCR technologies has the potential to open higher 
orders of multiplexing which can supersede current real-time 
PCR technology. PCR-MALDI detection of important fungal 
species was achieved and this approach could be transferred to 
any number of applications. With certain pathogens exhibiting 
poor culture sensitivity, the use of PCR-MALDI has the poten-
tial to become a key analytical tool in the microbiology and 
diagnostics field.
PCR is an important identification method, fast and ro-
bust [4]. The Sepsis Flow Chip (SFC) assay is based on multiplex 
PCR and low-density DNA arrays, which is a novel diagnos-
tic assay for simultaneous rapid-detection of the vast major-
ity of bloodstream pathogens, including Gram-positive and 
Gram-negative bacteria and fungi, in the same assay, and for 
the detection of most common antibiotic resistance genes [5]. 
SFC technique was used to analyse the blood cultures from 96 
stratified bacteremic patients (Krishnamoorthi S, et al; P1948). 
The overall sensitivity and specificity for bacterial identifica-
tion were 89.16% and 86.96%, respectively and sensitivity and 
specificity for the identification of antibiotic genetic resistance 
determinants were 85.89% and 100%, respectively. This new 
method appears to be a very promising molecular diagnostic 
tool by combining the high number of distinct pathogens and 
the genetic resistance determinants identified in a single as-
say, which will contribute to a rapid and accurate diagnosis of 
bacteremia. Further investigations should be done to evaluate 
the usefulness of this assay in combination with clinical multi-
disciplinary groups.
Another study evaluated the AMR Direct Flow Chip assay 
(Galiana A, et al; P2288). It detects the main genetic resistance 
determinants for gram-positive and gram-negative microor-
ganisms in a single step. This assay was compared to GS tech-
niques based on Chrom ID MRSA, VRE and Carba Smart com-
bined with a molecular approach to identify genetic resistant 
determinants. AMR assay showed sensitivity and specificity 
values close to 100% demonstrating its ability as a diagnostic 
test in MDR screening surveillance programs at intensive care 
units.
Immunochromatographic tests (ICT) are easy and quick 
alternative diagnostic techniques. The prevalence of CPE is 
increasing worldwide and the control of their spread is very 
important, so there were some studies evaluating immu-
no-chromatography devices for the rapid detection of carbap-
enemases. For example, K-set OOK® (Resende C, et al; P2332) 
proved to be a sensitive test (100%) for detecting KPC, OXA-
48 and OXA-163 producing Enterobacteriaceae directly from 
rectal swabs using enrichment broth in different incubation 
periods. However, since the test is designed to detect only KPC, 
OXA-48 and OXA-163, false negative results can occur due 
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BL-producing K. pneumonia. Emergence of TOL/Tz resistance 
may occur during the treatment of MDR/XDR P. aeruginosa 
infections in 10-15% of the cases. It is caused by structural 
mutations in intrinsic (AmpC) or acquired (OXAs) beta-lacta-
mases and typically shows ceftazidime-avibactam (CAZ-AVI) 
cross-resistance, but increased susceptibility to carbapenems 
and penicillins. Other potential low-level resistance mutations 
include specific large chromosomal deletions and PBP3 muta-
tions (Oliver A; S0387).
A review about CAZ-AVI resistance (Humphries RM; 
S0386) shows that combination of ceftazidime and avibac-
tam represents a potential alternative to carbapenems for the 
treatment of multidrug-resistant. Resistance is related to mu-
tation to KPC-2 or KPC-3 omega loop that increases affinity 
for CAZ but prevents binding of AVI. Mutations to KPC en-
zymes result in enhanced ceftazidime kinetics rather than re-
duced avibactam inhibition. In infections with CAZ resistance 
strains containing certain omega-loop substitutions, the effi-
cacy of the combination may be in question [10]. This mecha-
nism of resistance has been described in patients treated with 
CAZ-AVI, resulting in microbiological failures. Another mecha-
nism of resistance is due to the combination of increased KPC 
expression and reduced permeability in patients with no previ-
ous exposure to CAZ-AVI. With the increased use of CAZ-AVI, 
resistance will continue to emerge and plasmids carrying mu-
tant genes may disseminate by horizontal gene transfer [11].
Among Gram-positive bacteria, in one study performed 
in Barcelona (Càmara J, et al; P0456) 993 enterococci isolates 
were screened to know the prevalence of transferable linezolid 
resistance. Through PCR, transferable LZD-resistance was de-
tected in six Enterococcus faecalis (optrA n=5 and optrA plus 
cfr n=1), two of them showed linezolid MIC= 4 mg/L and three 
linezolid inhibition zone >19mm. The prevalence of the optrA 
gene among enterococci is low and linezolid breakpoints are 
not sensitive enough to detect transferable linezolid-resist-
ance, being necessary the screening through the antimicrobi-
al susceptibility testing of chloramphenicol. In another study, 
emergence of an Enterococcus faecium strain with variable 
susceptibility to vancomycin due to the vanX deletion was 
analysed. E. faecium carrying pHVH-V1511 is capable of no-
socomial transmission and may develop clinical resistance to 
vancomycin. These strains may not be detected using standard 
culture methods for vancomycin resistant enterococci (VRE) 
(Hansen T, et al; O1147).
Animals can act as reservoirs of antimicrobial resistance 
genes. Livestock-associated methicillin-resistant Staphylococ-
cus aureus has emerged. Pigs, veal calves and poultry play an 
important role as reservoirs. There is a scatter in the commu-
nity, which may be partly related to meat consumption and 
to livestock density. CC398, a new variant of MRSA that has 
emerged in animals, is at the dawn of its evolution, so close 
monitoring is necessary. In relation to molecular relatedness of 
ESBL/ampC E. coli, one study of Dorado-García A et al shows 
that isolates from the general population had higher similari-
ties with those from human clinical settings, surface and sew-
age water and wild birds, while similarities with livestock or 
For prediction of Mycobacterium tuberculosis resistance, 
whole genome sequencing (WGS) has its limitation by the 
need to isolate mycobacteria by culture. There was a study 
comparing WGS with Deeplex®- MycTB. This last uses NGS-
based targeted deep sequencing for simultaneous prediction 
of (hetero)resistance to 13 anti-TB drugs/drug classes, MTB 
genotyping and identification, directly on primary specimens 
(Gaudin C, et al; P1556). Compared to WGS, Deeplex-MycTB 
showed high accuracy for rapid identification of MTB drug 
resistance-associated mutations from clinical specimens. This 
assay represents an important clinical tool for rapid definition 
of an optimal patient’s treatment.
ANTIMICROBIAL RESISTANCE
Resistance to antibiotics is an important public health 
threat, which is aggravated by the lack of development of new 
antimicrobial agents [7]. The emergence of multidrug-resist-
ant Gram-negative bacteria is a growing problem worldwide. 
Colistin is one of the last resort antimicrobials for the treat-
ment of infections caused by multidrug-resistant Gram-neg-
ative bacteria but in recent years, the resistance is increasing 
[8, 9]. A study presented at ECCMID (Mendes AC, et al; P0417) 
analysed an outbreak of a KPC-3 and MCR-1 producing Kleb-
siella pneumoniae strain in Europe in 16 patients. All isolates 
belonged to ST45K24 except one (ST1112). In another study, 
the authors found that K. pneumoniae harbouring a mcr-1 
plasmid is able to survive polymyxin treatment in vitro and 
in vivo. Interestingly, even without mcr-1, polymixin resist-
ance can rapidly emerge after polymixin exposure (Nang SC, 
et al; P0420). Concerning MgrB gene, one study demonstrat-
ed that the inactivation of this gene is a common mechanism 
of colistin resistance among K. pneumoniae. The presence of 
identical mutations/insertions in isolates of the same ST and 
PFGE profile suggests the occurrence of clonal expansion and 
cross-transmission (Esposito EP, et al; P0423)
One study analysed the impact of the mechanism of re-
sistance to carbapenems in gram-negative on mortality, 264 
outbreaks reported in literature were included. The highest 
crude mortality was observed in K. pneumonia (KPC and OXA-
type had higher mortality than metallo-betalactamases (MBL)) 
followed by Acinetobacter baumannii (OXA-type was higher 
than MBL) and Pseudomonas aeruginosa. The highest failure 
rates in containing the outbreaks were observed in K. pneumo-
nia KPC (Pezzani MD, et al; P1052).
The European survey of carbapenemase-producing En-
terobacteriaceae (EuSCAPE) reveals that carbapenemase-pro-
ducing K. pneumonia isolates focus mainly on five “high-risk” 
clonal STs (11, 15, 101, 258, 512), founding evidence of ge-
ographical clustering of carbapenemase-containing plasmids. 
Spread of carbapenem resistant isolates is deeply connected to 
the movement of people who travel more within than between 
countries (David S, et al; 01149)
Ceftolozane-tazobactam (TOL/Tz) shows high activity 
against ESBL-producing Escherichia coli, but lower against ES-
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Another phase III study presented was REVIVE-2 where 
Iclaprim was non-inferior to vancomycin in the treatment of 
patients with acute bacterial skin and skin structure infections 
(O0424). In the same way, monotherapy with once-daily oral 
omadacyclin was non-inferior to twice-daily oral linezolid in 
the treatment of adults with skin and soft tissue infections and 
was safe and generally well tolerated as was shown in the OA-
SIS-2 phase III clinical trial presented (O0425).
Against multidrug resistant gramnegatives, the results 
of a randomized, controlled, phase 3 trial (RESTORE) compar-
ing imipenem-relebactam versus colistin and imipenem for 
treating imipenem-nonsusceptible bacterial infections (77% 
Pseudomonas, 55% Klebsiella), hospital-acquired/ventila-
tor-associated bacterial pneumonia (HABP/VABP), complicated 
intra-abdominal infection (cIAI), or complicated urinary tract 
infection (cUTI) were shown (O0427). Imipenem-relebactam 
treated patients had a favourable overall response, especial-
ly in the pneumonia groups (87.5% vs. 67.5%). By the other 
hand, excluding patients with prior antibiotic failure for se-
rious gramnegative infections on outcomes in TANGO II, a 
randomised, open-label comparative trial with best available 
therapy in patients with cUTI, acute pyelonephritis, HABP/VA-
BP, bacteremia, and cIAI, due to known or suspected carbap-
enem-resistant Enterobacteriaceae, meropenem-vaborbactam 
was associated with increased clinical cure and microbiologic 
cure. We have to wait for the results of phase III clinical tri-
al of aztreonam avibactam (vs. meropenem) in patients with 
intraabdominal infections and ventilator and/or hospital ac-
quired pneumoniae, which began in March last year. Cefider-
food reservoirs were lower [12] (Kluytmans AJW; SO392). One 
study analysed the genetic characteristics of mcr-1 carrying 
E. coli from companion animals. A total number of 434 E. coli 
isolated were recovered from 1439 nasal/rectal swabs of ani-
mals, 56 strains were resistant to colistin and 47 of them were 
mcr-1 positive, mainly located on the plasmids which belong 
to different Inc types. Seven of 35 pets food samples were de-
tected to be mcr-1 positive. Colistin resistant E. coli from com-
panion animals may represent a potential risk to human health 
(Lei L, et al; O1050).
NEW ANTIMICROBIAL AGENTS
After the global crisis caused by the threat of antimicro-
bial resistant bacteria, in the last five years, new agents have 
been developed on a fast track way and presented for the first 
time in the last ECCMID congress in Vienna in 2017. Some of 
them have been recently approved by the regulatory agencies 
and many of them are under examination of the phase II and 
III clinical trials. All this information was presented at the 28th 
ECCMID in Madrid and it is summarized in table 1 and 2.
Among the most important clinical trials, is worth to men-
tion the phase III clinical trials IMPACT 1 and 2, analysed effi-
cacy of oral cadazolid versus vancomycin in the treatment of 
Clostridium difficile associated diarrhoea (O0420). Cadazolid 
showed no inferiority in clinical cure in IMPACT 1 and similar 
results than vancomycin in sustained cure (no recurrence in one 
month). Cadazolid was safe, well tolerated and could potentially 
be an alternative therapy for Clostridium difficile infection.















Table 1  Novel betalactam and non-betalactam combinations agents for multidrug-resistant  
Gram-negatives
Class: aDiazabicyclooctane; bBoronic; cSulbactam like. MBL: metallo-betalactamases; NA: not applicable.
MDR: multidrug-resistant, PA: Pseudomonas aeruginosa, AB: Acinetobacter baumannii, SM: Stenotrophomonas maltophilia
No activity Some activity Good to excellent activity
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and Italy between January 2013 and August 2017, excluding 
patients with ongoing sepsis or cases where there was an un-
controlled source of infection. The team investigated several 
primary outcomes, including mortality, and whether a patient 
was readmitted to hospital or had to remain in hospital longer 
than 14 days. From the 306 patients who completed a 7-day 
course of antibiotics, the team discovered 46% experienced 
these primary outcomes, compared with 50% in the 298 pa-
tients who received a 14-day course.
Undoubtedly, these new antimicrobials are the hope for the 
future added to other strategies of therapy based in new uses of 
old antibiotics such as fosfomycin (Hutner et al. O1127; or com-
binations of them as well as the use of bacteriophages (SY040). 
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